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Penile squamous cell carcinoma (SCC) is an uncommon condition in Western countries. Inguinal lymph nodes dissection can
be curative in 20%–60% of node positive patients. However, there is a high complication rates from the dissection, thus accurate
diagnosis of inguinal lymph nodes metastasis is required. Current non invasive methods to detect lymph nodes metastasis are
unreliable. Dynamic Sentinel Node Biopsy (DNSB), ultrasonography (US), and ﬁne needle aspiration (FNA) cytology were
proposed to in an attempt to detect sentinel lymph node (SLN). Despite the initial high rate of false negative results, recent
DSNB showed improved survival compared to wait and see policy as well as reduced mortality compared to prophylactic
inguinal lymphadenectomy. In addition, the US guided FNA shown 100% of speciﬁcity in detecting clinically occult lymph nodes
metastasis. We proposed an algorithm for management of lymph nodes in penile cancer and suggest that FNA with US guidance
should be performed in all high risk patients and that therapeutic dissection should be performed if ﬁndings are positive.
Penile squamous cell carcinoma (SCC) is an uncommon
condition in western countries. It usually originates in the
epitheliumof the inner prepuceand glans. PenileSCChas an
incidenceoflessthan1per100,000malesand accountingfor
10%–20% of all malignancies in male patients in developing
nations [1].
Of patients presenting with penile SCC, 30%–60% have
enlarged lymph nodes in the groin. In about half of these
patients, this is caused by metastatic invasion and in the
other half by inﬂammatory reactions [2]. Nodal metastasis
will develop in 10%–15% of the patients presenting with no
clinical signs of nodal invasion [3].
SinceSCCofthe penis canbe surgically cured despite the
presence of inguinal lymph node metastasis, the appropriate
management of the lymph node is extremely important in
determining the treatment outcome. However, due to the
relatively low incidence of penile SCC, limited number of
patients’ reports, and the rarity of prospective randomized
trials, no clear guidelines for optimal treatment of patients
with penile SCC and lymph nodes have been established.
Inguinal lymph node dissection can be curative in 20%–
60% of node-positive patients. In node-negative men,
inguinal lymph node dissection does not guarantee survival
with a 5-year treatment failure rate of 5%–25% [4]. A
report on102patientsundergoingconservativemanagement
of the primary lesion (either brachytherapy or limited
surgery) found that 32% of those with local relapse died
compared with 75% of those with lymph node relapse,
showing that nodal relapse remains the major cause of death
[5].
Histologic grade and LVI are independent prognostic
factors for occult metastasis in penile carcinoma. Although
both predictors are incorporated into the current EAU
guidelines, the stratiﬁcation of patients needing a lymph
node dissection is inaccurate. Graaﬂand et al. describe that
approximately 77% of high-risk patients in their study
(188 of 245) would have had a negative bilateral inguinal
lymphadenectomy. For the time being, DSNB is considered
a more suitable staging method than EAU risk stratiﬁcation
for an accurate determination of patientswho require lymph
node dissection [6].2 Advances in Urology
Additionally, inguinal lymph node dissection has a rela-
tively high complication rate such as skin necrosis, seroma,
lymphocoele, leg lymphedema, DVT, and femoral neu-
rapraxia; hence, an accurate diagnosis of inguinal lymph
node in the context of penile SCC treatment is required.
Currently, the noninvasive methods to detect lymph
node metastasis are unreliable. However, there is a clinical
need to ﬁnd out real metastasis as soon as possible due
to survival beneﬁts demonstrated [4]. A surveillance policy
in negative-node patients risks a noncurable disease once
d e t e c t e d .O nt h ec o n t r a r y ,a ne a r l yi n g u i n a ll y m p h a d e n e c -
tomy in clinically node-negative patients is unnecessary in
up to 80% [7].
Severalmethodsofdetectingaclinicallyoccultmetastasis
have emerged: dynamic sentinel-node biopsy (DSNB),ultra-
sonography (US),and ﬁne-needle aspiration (FNA)cytology
of lymph nodes.
DSNB is performed by intradermal injection of techneti-
um-99m nanocolloid around the primary tumour, preoper-
ative, and intraoperative identiﬁcation of the sentinel lymph
node (SLN) with the aid of intradermally administered
patent blue dye and a gamma ray detection probe. The
theoretical advantage of these techniques is that it is a
functional rather than anatomical method of identifying
sentinel lymph node (SLN). Anatomical studies showed
that the SLN area has ≤7 lymph nodes located between
the superﬁcial epigastric and external pudendal veins [8].
Initially,sentinel nodebiopsywasnotrecommendedbecause
of a high rate of false-negative results (43%) [9]. However,
recently, DSNB showed an improved survival versus a
“wait and see” policy and reduced mortality compared
to prophylactic inguinal lymphadenectomy [10]. Similarly,
another European series demonstrated that DSNB has a
100% speciﬁcity and 95% sensitivity [11]a n dc o m p a r i s o n s
from two centres demonstrated that DSNB technique were
reproducible [12]. Overall, DSNB is recommended for
penile SCC with nonpalpable lymph nodes in EAU and
SIU guidelines [13, 14]. Additionally, Graaﬂand et al. [15]
stated DSNB after resection of primary tumour as a suitable
proceduretostageclinicallynode-negative penilecarcinoma,
with a 93% sentinel node visualization rate, identiﬁcation of
100% and detection of occult metastasis in 12% of clinically
node-negative groins.
FNA Cytology of inguinal lymph nodes has previously
been evaluated under diﬀerent clinical circumstances as a
mean of determining metastatic involvement from penile
carcinoma. Kumar et al. [16] reported 100% sensitivity of
FNA for the detection of metastatic penile carcinoma in
palpableinguinal lymphadenopathyinaseriesof28patients.
The FNA cytology was done at the time of inguinal node
dissection and not before antibiotic therapy. Despite the
sensitivity, they suggested that patients with negative FNA
should be subjected to medial inguinal lymph node biopsy
to overcome the risk of a false negative cytologic assessment.
Accurate sampling by FNA is often cited as an issue when
m a n yn o d e sa r ee n l a r g e d ,a si so f t e nt h ec a s e[ 16]. This has
lead to other methods of accurately identifying nodes for
cytologic assessment using lymphangiography and CT scan-
ning, which have been largely been discouraging [17–19].
Algorithm for management of
lymph nodes at penile cancer
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Figure 1
Just recently, Graaﬂand et al. used CT scan imaging to
describe the inguinal node features for positivity of involve-
ment (central nodal necrosis and/or an irregular nodal
border) [20].
Recently, Saisorn et al. [21]d e m o n s t r a t e dt h a tF N A
of palpable inguinal lymphadenopathy (no ultrasound was
performed during FNA) under local anaesthetic at the time
of biopsy of the primary penile SCC is safe and accurate
in predicting metastatic disease. They assessed a total of
16 patients with penile cancer and palpable lymph nodes,
performing at the time of primary lesion biopsy, an FNA of
palpable lymph nodes, partial penectomy, and synchronous
bilateral inguinal lymph node dissection. By using the
algorithm described by these authors, 52% of the patients
couldhavesparedthesix-weekperiodofantibiotictreatment
before proceeding to inguinal lymph node dissection, hence,
reporting a better survival on the long-term followup.
In relation to nonpalpable inguinal lymph nodes, Kroon
et al. [22] added the US for an accurate FNA. These authors
performed 34 groins USs and FNAs previous to DSNB. The
sensitivity of US-guided FNA in detecting clinically occult
lymph node metastases was 39% with 100% speciﬁcity.
This number showed to be similar to the ones used in
other cancer pathologies (breast, melanoma), where US pre-
DSNB is clearly established. This concludes that US-FNA
cannot replace DNSB but is a useful tool for preoperative
screening of clinically node-negative groins in patients
scheduled to undergo DNSB. Up to 10% of groin DNSB
can be avoided in favour of direct inguinal lymph node
dissection. In the eﬀort of improving the eﬃciency of US-
FNA, these authors suggested using an echogenic contrast to
diﬀerentiate pathologic features on lymph nodes as well as
increasing the US probe frequency.
Moreover, US-FNA has a role during followup after
DNSB as earlier detection of recurrences might be expected.
However, no randomized control trials have proven that
statement.
In conclusion, we suggest/recommend that FNA with US
guidance may be performed in all patients with or withoutAdvances in Urology 3
clinically palpable nodes especially in those who are at high
risk of lymph nodes involvement (Figure 1). If the ﬁndings
are positive, therapeutic, rather than diagnostic, inguinal
lymph node dissection can be performed [14].
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